Drugs / Mesenchymal Precursor Cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02362646 | Jul 2015 → Aug 2018 | cardiac ventricle disorder, cardiomyopathy, heart failure | Annetine Gelijns | Completed | No outcome recorded |
| Phase 2 | NCT01781390 | Mar 2013 → Apr 2021 | acute myocardial infarction | Mesoblast, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01442129 | Apr 2012 → Mar 2013 | cardiac ventricle disorder, cardiomyopathy, heart failure | Deborah Ascheim | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mesenchymal precursor cells | “Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation” NCT02362646 ↗2“Intramyocardial injection of 25 million mesenchymal precursor cells at the time of LVAD implantation” NCT01442129 ↗ |
| Known as | MPC | “mesenchymal precursor cells (MPC) into the heart during surgery” NCT01442129 ↗1“Mesenchymal Precursor Cells (MPC) 12.5 M” NCT01781390 ↗ |
| Modality | Cell therapy | “Allogeneic mesenchymal precursor cells (MPCs) injected during left ventricular assist device (LVAD) implantation” PMID 24682346 ↗ Mar 2014 |
| Route | Other | “Intramyocardial injection of 25 million mesenchymal precursor cells at the time of LVAD implantation” NCT01442129 ↗ |